Medexus Pharmaceuticals Inc. (MEDXF)
| Market Cap | 112.68M +84.0% |
| Revenue (ttm) | 103.30M -2.2% |
| Net Income | -2.37M |
| EPS | -0.07 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,400 |
| Open | 3.670 |
| Previous Close | 3.580 |
| Day's Range | 3.670 - 3.870 |
| 52-Week Range | 1.800 - 3.860 |
| Beta | 1.84 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 11, 2026 |
About Medexus Pharmaceuticals
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis, psoriasis, and juvenile idiopathic arthritis; Rupall, a prescription allergy medication; and GRAF... [Read more]
Financial Performance
Financial StatementsNews
Medexus Pharmaceuticals Earnings Call Transcript: Q1 2027
First quarter results showed strong revenue and EBITDA growth, led by GRAFAPEX's record performance and broad adoption, especially in the adult segment. Strategic expansion in Allo-HSCT and stable performance from established products support a positive outlook.
Medexus Pharmaceuticals Registration statement: Q1 2027
Medexus Pharmaceuticals filed a registration statement on August 11, 2026, providing details about a securities offering with the SEC.
Medexus Pharmaceuticals Registration statement: Q1 2027
Medexus Pharmaceuticals filed a registration statement on August 11, 2026, providing details about a securities offering with the SEC.
Medexus Pharmaceuticals Earnings release: Q1 2027
Medexus Pharmaceuticals released its Q1 2027 earnings on August 11, 2026, summarizing the period's financial results.
Medexus Announces Fiscal Q1 2027 Results With Strongest Quarter of Product-Level Performance of GRAFAPEX (Treosulfan) to Date
Fiscal Q1 2027 includes product-level net revenue from GRAFAPEX™ (treosulfan) for Injection of $4.9 million relative to $3.2 million of GRAFAPEX personnel and infrastructure investments Commercial tra...
Medexus Schedules First Fiscal Quarter 2027 Conference Call
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - July 30, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Tuesday, August ...
Medexus Pharmaceuticals Earnings Call Transcript: Q4 2026
FY2026 saw GRAFAPEX drive growth, offsetting declines from Gleolan and Rupall, with net revenue at $99.3M and adjusted EBITDA at $16.5M. GRAFAPEX is projected to reach $30–$32M in FY2027, while established products are expected to remain stable.
Medexus Pharmaceuticals Earnings release: Q4 2026
Medexus Pharmaceuticals released its Q4 2026 earnings on June 26, 2026, summarizing the period's financial results.
Medexus Pharmaceuticals Registration statement: Q4 2026
Medexus Pharmaceuticals filed a registration statement on June 26, 2026, providing details about a securities offering with the SEC.
Medexus Announces Fiscal Year 2026 Results, Demonstrating Continued Momentum and Strong Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Management to host conference call at 8:00 AM Eastern time on Friday, June 26, 2026 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 25, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX...
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2026 Conference Call
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 16, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Friday, June 26,...
Medexus Announces License and Supply Deal for UM171 Cell Therapy in Canada
UM171 Cell Therapy is conditionally approved in Europe as Zemcelpro® (dorocubicel) Securing Canadian rights to a proprietary advanced clinical-stage product candidate developed in Canada adds to Medex...
Medexus Pharmaceuticals Transcript: 16th Annual LD Micro Invitational Conference
Revenue and EBITDA remain stable, with growth now driven by GRAFAPEX, an orphan drug for AML and MDS showing strong early adoption and clinical outcomes. The company is focused on expanding its rare disease portfolio through accretive acquisitions and expects to more than double revenue in the coming years.
Medexus Pharmaceuticals Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference
A diversified pharma portfolio is driving steady revenue and EBITDA, with GRAFAPEX poised to double revenue at high margins. Strong hospital uptake, favorable reimbursement, and robust clinical data support U.S. peak sales of $100–$175 million within 3–5 years.
Medexus Provides Business Update on GRAFAPEX (treosulfan) for Injection, Capital Allocation, and Investor Conference Participation
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 15, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today provided an operational business update on the ongoing commercializa...
Medexus Pharmaceuticals Slides: Investor presentation
Medexus Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on March 18, 2026.
Medexus Pharmaceuticals Earnings Call Transcript: Q3 2026
GRAFAPEX continues to drive growth, with strong adoption and improving gross margins, despite overall revenue declines due to generic competition and product returns. Cash flow and balance sheet strength have improved, supporting ongoing investments and share repurchases.
Medexus Pharmaceuticals Earnings release: Q3 2026
Medexus Pharmaceuticals released its Q3 2026 earnings on February 12, 2026, summarizing the period's financial results.
Medexus Announces Fiscal Q3 2026 Results, Driven by Continued Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Management to host conference call at 8:00 AM Eastern time on Thursday, February 12, 2026 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 11, 2026) - Medexus Pharmaceuticals (TSX: M...
Medexus Schedules Third Fiscal Quarter 2026 Conference Call
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 3, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, Feb...
Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Common Shares
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 20, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the Toronto Stock Exchange has accepted Med...
Medexus Announces US$51.0 million in New Credit Facilities and Intention to Commence Normal Course Issuer Bid, or NCIB, for its Common Shares
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 17, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today entered into a new senior secured credit agreement with National ...
Medexus Pharmaceuticals Earnings Call Transcript: Q2 2026
Graphopex outperformed expectations, driving strong adoption and positive feedback, with guidance for continued revenue growth and positive cash flow in fiscal Q3 2026. Portfolio performance was mixed, with generic competition impacting some products and gross margin improving year-over-year.
Medexus Pharmaceuticals Earnings release: Q2 2026
Medexus Pharmaceuticals released its Q2 2026 earnings on November 13, 2025, summarizing the period's financial results.
Medexus Announces Fiscal Q2 2026 Results, Driven by Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Management to host conference call at 8:00 AM Eastern time on Thursday, November 13, 2025 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 12, 2025) - Medexus Pharmaceuticals (TSX: M...